CVS Health Corporation $CVS Stock: Nvwm LLC Increases Stake

Nvwm LLC grew its position in CVS Health Corporation (NYSE:CVS) by 12,778.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 6,697 shares of the pharmacy operator’s stock after purchasing an additional 6,645 shares during the period. Nvwm LLC’s holdings in CVS Health were worth $574,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Elevation Wealth Partners LLC lifted its position in shares of CVS Health by 41.8% during the 2nd quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator’s stock worth $37,000 after buying an additional 105 shares in the last quarter. HBW Advisory Services LLC grew its holdings in shares of CVS Health by 3.5% in the third quarter. HBW Advisory Services LLC now owns 3,408 shares of the pharmacy operator’s stock valued at $292,000 after acquiring an additional 115 shares in the last quarter. Apella Capital LLC grew its holdings in shares of CVS Health by 1.7% in the second quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator’s stock valued at $724,000 after acquiring an additional 117 shares in the last quarter. Wellington Altus USA Inc. increased its position in shares of CVS Health by 13.3% during the second quarter. Wellington Altus USA Inc. now owns 1,025 shares of the pharmacy operator’s stock valued at $106,000 after acquiring an additional 120 shares during the last quarter. Finally, CoreCap Advisors LLC increased its position in shares of CVS Health by 4.2% during the second quarter. CoreCap Advisors LLC now owns 3,481 shares of the pharmacy operator’s stock valued at $360,000 after acquiring an additional 139 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Stock Up 2.3%

CVS Health stock opened at $92.45 on Friday. The firm has a 50 day moving average price of $91.80 and a 200-day moving average price of $93.03. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. CVS Health Corporation has a twelve month low of $69.51 and a twelve month high of $110.68. The company has a market capitalization of $118.25 billion, a P/E ratio of 24.46, a P/E/G ratio of 0.84 and a beta of 0.60.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. During the same quarter in the previous year, the firm posted $1.81 EPS. CVS Health’s revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities analysts predict that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd will be paid a $0.6650 dividend. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 annualized dividend and a dividend yield of 2.9%. CVS Health’s payout ratio is presently 70.37%.

Analysts Set New Price Targets

CVS has been the topic of a number of recent analyst reports. HSBC reiterated a “hold” rating and set a $103.00 price target on shares of CVS Health in a report on Monday, July 6th. Piper Sandler set a $112.00 price objective on CVS Health in a research note on Wednesday, September 9th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CVS Health in a research report on Friday, October 9th. Bank of America lifted their target price on CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Finally, Argus boosted their price target on shares of CVS Health from $104.00 to $114.00 and gave the stock a “buy” rating in a report on Wednesday, August 19th. Twenty investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $107.80.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Improving fundamentals and valuation support the stock. CVS has recently exceeded earnings and revenue expectations, while analysts cited stronger returns, rising earnings estimates and a lower valuation than Alignment Healthcare. Its Aetna turnaround is also viewed as a potential catalyst. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
• Positive Sentiment: Expanded care access and quality credentials reinforce CVS’s healthcare-services strategy. CVS opened its first pharmacy-focused location in the Boston area to improve access to medications, immunizations and other services. Separately, MinuteClinic received its seventh consecutive Joint Commission accreditation, with primary care available at more than 65% of its locations. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
• Neutral Sentiment: New women’s-health collaboration could support longer-term engagement. CVS is partnering with The Midlife Collective on a research study and documentary focused on women’s midlife health. The initiative may strengthen brand awareness and consumer relationships, but it is unlikely to have a near-term financial impact. CVS Health Collaborates With The Midlife Collective
• Positive Sentiment: Home-based heart monitoring expands value-added services. Signify Health, part of CVS, offers continuous heart-rhythm monitoring for eligible health-plan members, potentially enabling earlier detection of serious conditions and supporting preventive-care economics. CVS Health: Early Detection Matters
• Negative Sentiment: $315 million opioid settlement creates legal, financial and reputational pressure. CVS agreed to settle Justice Department allegations involving unlawful opioid dispensing and false claims. The company admitted no wrongdoing but will implement tighter controlled-substance oversight, adding costs and highlighting compliance risks. CVS Agrees to Pay $315M

About CVS Health

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.